Scalper1 News
Big pharma AbbVie (ABBV) said Friday that it’s advancing a rheumatoid arthritis drug after successful midstage clinical trials, but it’s also bailing out of a similar drug being developed by Belgian biotech Galapagos (GLPG), sending the latter’s stock tumbling. AbbVie conducted two trials testing various doses of ABT-494 against a placebo: one studying patients who responded inadequately to methotrexate, the other looking at those who failed to Scalper1 News
Scalper1 News